A tripartite complex of suPAR, APOL1 risk variants and α v β 3 integrin on podocytes mediates chronic kidney disease

Nature Medicine

Volumn 23, Issue 8, 2017, Pages 945-956

  Hayek, Salim S ^a   Koh, Kwi Hye ^b   Grams, Morgan E ^c   Wei, Changli ^b   Ko, Yi An ^d   Li, Jing ^b   Samelko, Beata ^b   Lee, Hyun ^e   Dande, Ranadheer R ^b   Lee, Ha Won ^b   Hahm, Eunsil ^b   Peev, Vasil ^b   Tracy, Melissa ^b   Tardi, Nicholas J ^b   Gupta, Vineet ^b   Altintas, Mehmet M ^b   Garborcauskas, Garrett ^f   Stojanovic, Nikolina ^f   Winkler, Cheryl A ^g   Lipkowitz, Michael S ^h   Tin, Adrienne ^c   Inker, Lesley A ⁱ   Levey, Andrew S ⁱ   Zeier, Martin ^j   Freedman, Barry I ^k   Kopp, Jeffrey B ^l   Skorecki, Karl ^m   Coresh, Josef ^c   Quyyumi, Arshed A ^a   Sever, Sanja ^f   Reiser, Jochen ^b   more..

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d EMORY UNIVERSITY   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g NATIONAL CANCER INSTITUTE   (United States)

^h GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

ⁱ TUFTS MEDICAL CENTER   (United States)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k WAKE FOREST SCHOOL OF MEDICINE   (United States)

^l NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^m TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN L1; PROTEIN VARIANT; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VITRONECTIN RECEPTOR; APOL1 PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN PROTEIN INTERACTION; PROTEINURIA; RISK ASSESSMENT; SURFACE PLASMON RESONANCE; ADOLESCENT; AFRICAN AMERICAN; AGED; ALLELE; ANIMAL; GENETIC PREDISPOSITION; GENETICS; METABOLISM; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGED; ALLELES; ANIMALS; APOLIPOPROTEINS; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTEGRIN ALPHAVBETA3; LIPOPROTEINS, HDL; MALE; MICE; MIDDLE AGED; PODOCYTES; PROTEINURIA; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RENAL INSUFFICIENCY, CHRONIC; SURFACE PLASMON RESONANCE; YOUNG ADULT;

EID: 85027721296     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.4362     Document Type: Article

References (46)

1. Chen, T.K., Estrella, M.M. & Parekh, R.S. The evolving science of apolipoprotein-L1 and kidney disease. Curr. Opin. Nephrol. Hypertens. 25, 217-225 (2016).
2. Tzur, S. et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum. Genet. 128, 345-350 (2010).
3. Genovese, G. et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 329, 841-845 (2010).
4. Kao, W.H. et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat. Genet. 40, 1185-1192 (2008).
5. Parsa, A. et al. APOL1 risk variants, race, and progression of chronic kidney disease. N. Engl. J. Med. 369, 2183-2196 (2013).
6. Nichols, B. et al. Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. Kidney Int. 87, 332-342 (2015).
7. Papeta, N. et al. APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J. Am. Soc. Nephrol. 22, 1991-1996 (2011).
8. Kopp, J.B. et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J. Am. Soc. Nephrol. 22, 2129-2137 (2011).
9. Bruggeman, L.A. et al. APOL1-G0 or APOL1-G2 transgenic models develop preeclampsia but not kidney disease. J. Am. Soc. Nephrol. 27, 3600-3610 (2016).
10. Anderson, B.R. et al. In vivo modeling implicates APOL1 in nephropathy: evidence for dominant negative effects and epistasis under anemic stress. PLoS Genet. 11, e1005349 (2015).
11. Thunø, M., Macho, B. & Eugen-Olsen, J. suPAR: the molecular crystal ball. Dis. Markers 27, 157-172 (2009).
12. Sidenius, N. et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodefciency virus infection. Blood 96, 4091-4095 (2000).
13. Ostrowski, S.R. et al. High plasma levels of intact and cleaved soluble urokinase receptor refect immune activation and are independent predictors of mortality in HIV-1-infected patients. J. Acquir. Immune Defc. Syndr. 39, 23-31 (2005).
14. Hayek, S.S. et al. Soluble urokinase receptor and chronic kidney disease. N. Engl. J. Med. 373, 1916-1925 (2015).
15. Hahm, E. et al. Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease. Nat. Med. 23, 100-106 (2017).
16. Wei, C. et al. Modifcation of kidney barrier function by the urokinase receptor. Nat. Med. 14, 55-63 (2008).
17. Wei, C. et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat. Med. 17, 952-960 (2011).
18. Weckerle, A. et al. Characterization of circulating APOL1 protein complexes in African Americans. J. Lipid Res. 57, 120-130 (2016).
19. Ni, H., Li, A., Simonsen, N. & Wilkins, J.A. Integrin activation by dithiothreitol or Mn2+ induces a ligand-occupied conformation and exposure of a novel NH2-terminal regulatory site on the beta1 integrin chain. J. Biol. Chem. 273, 7981-7987 (1998).
20. Bruggeman, L.A. et al. Plasma apolipoprotein L1 levels do not correlate with CKD. J. Am. Soc. Nephrol. 25, 634-644 (2014).
21. Lan, X. et al. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability. Am. J. Physiol. Renal Physiol. 307, F326-F336 (2014).
22. Wan, G. et al. Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. J. Biol. Chem. 283, 21540-21549 (2008).
23. Tanida, I., Ueno, T. & Kominami, E. LC3 and autophagy. Methods Mol. Biol. 445, 77-88 (2008).
24. Sever, S. et al. Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. J. Clin. Invest. 117, 2095-2104 (2007).
25. Yaddanapudi, S. et al. CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival. J. Clin. Invest. 121, 3965-3980 (2011).
26. Shukha, K. et al. Most ApoL1 is secreted by the liver. J. Am. Soc. Nephrol. 28, 1079-1083 (2016).
27. Fu, Y. et al. APOL1-G1 in nephrocytes induces hypertrophy and accelerates cell death. J. Am. Soc. Nephrol. 28, 1106-1116 (2017).
28. Ma, L. et al. APOL1 renal-risk variants induce mitochondrial dysfunction. J. Am. Soc. Nephrol. 28, 1093-1105 (2017).
29. Friedman, D.J. & Pollak, M.R. Apolipoprotein L1 and kidney disease in African Americans. Trends Endocrinol. Metab. 27, 204-215 (2016).
30. Kruzel-Davila, E. et al. APOL1-mediated cell injury involves disruption of conserved traffcking processes. J. Am. Soc. Nephrol. 28, 1117-1130 (2017).
31. Cortese, K., Sahores, M., Madsen, C.D., Tacchetti, C. & Blasi, F. Clathrin and LRP-1-independent constitutive endocytosis and recycling of uPAR. PLoS One 3, e3730 (2008).
32. Czekay, R.P., Kuemmel, T.A., Orlando, R.A. & Farquhar, M.G. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mol. Biol. Cell 12, 1467-1479 (2001).
33. Yu, C.H. et al. Integrin-β3 clusters recruit clathrin-mediated endocytic machinery in the absence of traction force. Nat. Commun. 6, 8672 (2015).
34. Kobayashi, N. et al. Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via uPAR-mediated β1-integrin endocytosis. Am. J. Physiol. Renal Physiol. 308, F614-F626 (2015).
35. Outinen, T.K. et al. Urine soluble urokinase-type plasminogen activator receptor levels correlate with proteinuria in Puumala hantavirus infection. J. Intern. Med. 276, 387-395 (2014).
36. Gavrilovskaya, I.N., Shepley, M., Shaw, R., Ginsberg, M.H. & Mackow, E.R. β3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proc. Natl. Acad. Sci. USA 95, 7074-7079 (1998).
37. Beckerman, P. et al. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice. Nat. Med. 23, 429-438 (2017).
38. + progenitor cells and risk of mortality in a population with coronary artery disease. Circ. Res. 116, 289-297 (2015).
39. Eapen, D.J. et al. Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events. J. Am. Heart Assoc. 3, e001118 (2014).
40. Levey, A.S. et al. A new equation to estimate glomerular fltration rate. Ann. Intern. Med. 150, 604-612 (2009).
41. Lee, H. et al. Reducing agents affect inhibitory activities of compounds: results from multiple drug targets. Anal. Biochem. 423, 46-53 (2012).
42. Saleem, M.A. et al. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J. Am. Soc. Nephrol. 13, 630-638 (2002).
43. Wu, M.J. et al. Rapamycin promotes podocyte migration through the up-regulation of urokinase receptor. Transplant. Proc. 46, 1226-1228 (2014).
44. Li, Y. et al. An anti-urokinase plasminogen activator receptor (uPAR) antibody: crystal structure and binding epitope. J. Mol. Biol. 365, 1117-1129 (2007).
45. Foster, M.C. et al. APOL1 variants associate with increased risk of CKD among African Americans. J. Am. Soc. Nephrol. 24, 1484-1491 (2013).
46. Harrell, F. Regression Modeling Strategies: with Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis (Springer, 2015).